Drug Profile
Etonogestrel sustained release - Orbis Biosciences
Alternative Names: DARE 204/214; DARE-204; DARE-214; ORB 204; ORB 214Latest Information Update: 21 Jul 2023
Price :
$50
*
At a glance
- Originator Orbis Biosciences
- Class Hormonal contraceptives; Norpregnanes; Phenanthrenes; Progesterone congeners; Small molecules
- Mechanism of Action Progesterone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Pregnancy
Most Recent Events
- 07 Jul 2023 Dare Bioscience plans to initiate a phase I trial in Pregnancy
- 17 May 2022 Etonogestrel sustained release is still in preclinical phase for Pregnancy (Prevention) in US (Dare Bioscience pipeline, May 2022)
- 28 Apr 2022 No recent reports of development identified for preclinical development in Pregnancy(Prevention) in USA (SC, Injection)